Rigel Pharmaceuticals this morning announced that it entered into a Tavalisse partnership with Kissei Pharmaceuticals to develop and commercialize the drug in Japan, China, Taiwan, and the Republic of Korea, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. The company had been projecting Asian and European partnerships by mid-2019, and the first has now been delivered well ahead of schedule, says the analyst. He believes Rigel is also likely to deliver on the Europe deal ahead of schedule as well. The analyst reiterates a Buy rating on Rigel Pharmaceuticals with a $7.50 price target.